Crescent Biopharma
CBIO
84 hedge funds and large institutions have $707M invested in Crescent Biopharma in 2018 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 22 closing their positions.
205% more call options, than puts
Call options by funds: $6.31M | Put options by funds: $2.06M
106% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 16
32% more capital invested
Capital invested by funds: $535M → $707M (+$171M)
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
5% more funds holding
Funds holding: 80 → 84 (+4)
0.13% more ownership
Funds ownership: 0.93% → 1.06% (+0.13%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$52.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$45.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$34.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$33.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$8.35M |
| 2 |
NC
Nexthera Capital
New York
|
-$8.07M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$4.82M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$4.38M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.7M |
CBIO Hedge Fund Activity: Q1 2018 in Review
84 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2018, worth a combined $707M — up 32% from $535M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CBIO positions and 22 closed out — a net gain of 5 holders — while 33 added to existing stakes and 16 trimmed.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $52.1M. The largest seller was BVF Inc, exiting entirely with an estimated $8.35M sold.
- 84 institutional investors held Crescent Biopharma (CBIO) as of Q1 2018, up from 80 in Q4 2017.
- Funds reported $707M of Crescent Biopharma stock for Q1 2018, up 32% quarter-over-quarter.
- 27 funds opened new Crescent Biopharma positions in Q1 2018 and 22 closed out, a net change of +5 holders.
- The largest Crescent Biopharma buyer in Q1 2018 was OppenheimerFunds, an estimated $52.1M added.
- The largest Crescent Biopharma seller in Q1 2018 was BVF Inc, an estimated $8.35M sold.
Based on aggregated 13F filings for Q1 2018.